Raltegravir dosage adjustment in HIV-infected patients receiving etravirine

被引:7
作者
Do, Vi T. [2 ]
Higginson, Robert T.
Fulco, Patricia Pecora [1 ]
机构
[1] Virginia Commonwealth Univ, Med Ctr, Div Infect Dis, Richmond, VA 23298 USA
[2] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA
关键词
Antiretroviral agents; Blood levels; Darunavir; Dosage; Drug interactions; Enfuvirtide; Etravirine; HIV infections; Mechanism of action; Pharmacokinetics; Raltegravir; Ritonavir; EXPERIENCED HIV-1-INFECTED PATIENTS; PLACEBO-CONTROLLED TRIAL; TMC125; ETRAVIRINE; DOUBLE-BLIND; PHARMACOKINETICS; RESISTANT; DARUNAVIR/RITONAVIR; EFFICACY; FAILURE; REGIMEN;
D O I
10.2146/ajhp110083
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose. The pharmacokinetic interaction of etravirine and raltegravir is reviewed, with discussion of implications for clinical practice. Summary. Etravirine (a second-generation nonnucleoside reverse transcriptase inhibitor) and raltegravir (an integrase strand-transfer inhibitor) are two agents approved, by the Federal Food and Drug Administration for use in human immunodeficiency virus (HIV) treatment-resistant patients. Minimal data exist on the concurrent use of raltegravir with etravirine. This combination would offer treatment-experienced HIV patients a novel pharmacotherapy plan including two new fully active agents. Etravirine induces uridine diphosphate-glucuronosyltransferase 1A1 and reduces the raltegravir minimum concentration (C-min) by 34% when administered concurrently in healthy volunteers. In a case series of four HIV treatment-resistant patients initiated on an antiretroviral regimen including standard doses of etravirine and raltegravir, poor virological control was demonstrated. Two of these four patients had a raltegravir C-min below the 95% minimum inhibitory concentration. In a larger study (n = 103), sustained virological control (viral loads of <50 copies/mL) resulted when HIV treatment-resistant patients received standard doses of darunavir, ritonavir, etravirine, raltegravir, and nucleoside analogs with or without enfuvirtide. Debate exists regarding the best raltegravir pharmacokinetic parameter to evaluate (C-min or the area under the concentration curve/50% effective concentration). Recent data in HIV treatment-naive patients support a negative association between a low raltegravir C-min (<= 43 ng/mL) and virological suppression. Conclusion. The need to adjust the dosage of raltegravir in HIV-infected patients who are also receiving etravirine is unclear. In such patients who have an extensive history of HIV disease treatment, prescribing raltegravir 1200 mg/day, rather than the standard 800 mg/day, may be prudent to prevent the development of treatment-resistant virus and to achieve an optimal virological response.
引用
收藏
页码:2049 / 2054
页数:6
相关论文
共 34 条
[31]  
Wenning LA, 2008, INT WORKSH PHARM HIV
[32]  
Wenning LA, 2008, INT C ANT AG CHEM IN
[33]   High Rate of Virologic Suppression with Raltegravir plus Etravirine and Darunavir/Ritonavir among Treatment-Experienced Patients Infected with Multidrug-Resistant HIV: Results of the ANRS 139 TRIO Trial [J].
Yazdanpanah, Y. ;
Fagard, C. ;
Descamps, D. ;
Taburet, A. M. ;
Colin, C. ;
Roquebert, B. ;
Katlama, C. ;
Pialoux, G. ;
Jacomet, C. ;
Piketty, C. ;
Bollens, D. ;
Molina, J. M. ;
Chene, G. .
CLINICAL INFECTIOUS DISEASES, 2009, 49 (09) :1441-1449
[34]  
Zheng S, 2011, C RETR OPP INF BOST